• A40926: Workflow for Cell Wall Antibiotic Research

  2026-10-02

  A40926 is a dalbavancin precursor and mechanistically defined glycopeptide for profiling cell wall inhibition, MRSA susceptibility, and the unusual activity of Neisseria gonorrhoeae. This practical guide connects reference MIC methods with assay design, biosynthetic research, comparative benchmarking, and troubleshooting.

• EPZ-6438: Mapping EZH2-Driven Resistance

  2026-10-01

  EPZ-6438 is a selective EZH2 inhibitor that turns H3K27me3 modulation into a practical tool for dissecting therapy resistance. This article connects its biochemical selectivity with time-resolved melanoma assays, model selection, and interpretation of combination experiments.

• TACE Silencing in Visceral Adipose Macrophages

  2026-10-01

  The 2017 Biomaterials study developed an ATS-9R-based nonviral system for preferential delivery of TACE-silencing cargo to visceral adipose tissue macrophages. By reducing TACE expression in these inflammatory cells, the approach attenuated adipose inflammation and improved obesity-associated type 2 diabetes in mice, providing a mechanistic framework for targeted obesity-associated inflammation research.

• 3D Cardiac Organoid Mapping with Shell MEAs

  2026-09-30

  The reference study introduces shape-adaptive shell microelectrode arrays (MEAs) that conform to cardiac organoids and enable three-dimensional mapping of electrical activation and conduction. By combining electrophysiology, calcium imaging, and pharmacological perturbations including E-4031, the platform provides a practical framework for longitudinal cardiac electrophysiology research and more physiologically informed drug-response analysis.

• ATS-9R for Adipose Gene Silencing Workflows

  2026-09-30

  ATS-9R provides a non-viral route for concentrating shRNA, siRNA, and selected genome-editing cargos in white adipose tissue and adipose tissue macrophages. Its most distinctive use-case is pairing Prohibitin-directed delivery with cell-specific inflammatory readouts for obesity, insulin resistance, and gestational diabetes research.

• Cepharanthine Workflows for Organoid Apoptosis

  2026-09-29

  Cepharanthine supports a staged workflow that moves from stromal-cell viability screening to patient-derived endometrial organoids and lesion-level validation. This article translates its reported apoptosis, DNA-damage, and cell-cycle effects into practical assay choices while separating preclinical endometriosis evidence from oncology applications.

• Dacomitinib Workflows for Pan-HER Cancer Research

  2026-09-29

  Dacomitinib (PF-00299804) supports practical studies of ErbB signaling, apoptosis, cell-cycle arrest, and treatment resistance. This guide also shows how to extend pan-HER experiments into exploratory ferroptosis and mitochondrial-function assays without confusing hypothesis generation with established mechanism.

• ATS-9R/siCcl2 Targets ATMs in GDM

  2026-09-28

  The reference study developed an ATS-9R/siCcl2 complex to suppress Ccl2 expression in adipose tissue macrophages and reduce inflammation-associated insulin resistance in gestational diabetes mellitus. Its main contribution is a cell- and tissue-oriented nonviral delivery strategy supported by human tissue observations, macrophage experiments, and an HFD-induced GDM mouse model.

• How Kinase Inhibitors Promote p38α Dephosphorylation

  2026-09-28

  A preprint reports that three kinase inhibitors both inhibit p38α MAP kinase and accelerate its dephosphorylation by WIP1. Structural comparisons suggest that inhibitor binding exposes an activation-loop phospho-threonine, revealing a way to influence kinase shutdown through conformational control rather than phosphatase recruitment.

• 2'3'-cGAMP (Sodium Salt): STING Research Guide

  2026-09-27

  2'3'-cGAMP (sodium salt) is an endogenous second messenger and direct STING activator used to investigate the cGAS-STING signaling pathway. Its reported high-affinity binding and defined formulation data make it useful for pathway studies, while extracellular degradation and cellular delivery remain important experimental limits.

• Bay 11-7821: Separating NF-κB from HMGB1 Release

  2026-09-26

  Bay 11-7821 (BAY 11-7082) is commonly used to perturb IKK/NF-κB signaling, but inflammatory outputs do not all share the same upstream controls. This article connects its use to lactate-driven HMGB1 release research and explains how to distinguish pathway effects from changes in cell viability or secretion.

• HNF4A-AS1 Loss Promotes Sorafenib Resistance in HCC

  2026-09-25

  A 2024 study identifies liver-enriched lncRNA HNF4A-AS1 as a regulator of sorafenib-induced ferroptosis in hepatocellular carcinoma. Its mechanistic model links HNF4A-AS1 to m6A-dependent degradation of DECR1 mRNA, altered polyunsaturated fatty acid content, and drug response, suggesting a testable route for investigating lipid-metabolism-associated resistance.

• FAM83A Links CK1, Mitochondria, and Adipogenesis

  2026-09-25

  Huang and colleagues identify FAM83A as a positive regulator of white adipocyte differentiation, connecting casein kinase 1 (CK1) activity with mitochondrial outer-membrane organization and lipogenesis. Their cell and mouse experiments use adipose-targeted CRISPR delivery to examine FAM83A loss, revealing reduced fat deposition alongside mitochondrial impairment—an important distinction when interpreting adipose tissue as a metabolic organ.

• CLCC1 Drives Herpesvirus Nuclear Egress Fusion

  2026-09-24

  A genome-wide CRISPR screen identified the host protein CLCC1 as a factor required for herpes simplex virus 1 nuclear egress. The findings distinguish a membrane-fusion defect from the earlier capsid-budding step and connect viral egress to nuclear pore insertion, while leaving CLCC1’s precise molecular action unresolved.

• DAPI in Disc-Degeneration Cell-State Assays

  2026-09-24

  DAPI is more than a nuclear counterstain: its membrane-dependent uptake can help separate viable from membrane-compromised cells in studies of nucleus pulposus senescence and macrophage crosstalk. This guide explains how to use DAPI thoughtfully alongside, not in place of, inflammatory and metabolic readouts.

7978 records 1/532 page Next 12345 下5页 Last page